Foundayo (orforglipron) vs the shots: the trial numbers side by side

Reviewed 13 sourcesPublished by PepVault

Foundayo (orforglipron) is a daily GLP-1 pill, not a peptide. Its ATTAIN and ACHIEVE results beside Zepbound's SURMOUNT and Wegovy's STEP, in one table.

A woman in an orange crop top holding a warrior-two pose on a hilltop at sunrise
Last reviewed
Sources
13
Questions
8
Compounds
4

The short answer

Foundayo is orforglipron, a once-daily GLP-1 pill from Eli Lilly that FDA approved for weight on April 1, 2026. It is a small chemical molecule, not a peptide, and it can be taken with or without food. On its top dose, 17.2 mg, weight fell 11.1% on average in 72 weeks, against about 21% on Zepbound and 15 to 19% on the Wegovy shot, in separate trials.

Every number checked at its primary source · · 13 sources · How we research

Evidence: Strong for what it claims: large randomized phase 3 trials in people (ATTAIN-1 and -2, ACHIEVE-1 to -4, ATTAIN-MAINTAIN) and the FDA labels; no trial has compared Foundayo with Zepbound or the Wegovy shot head to head.

A woman in an orange crop top holding a warrior-two pose on a hilltop at sunrise

What is Foundayo, and is it a peptide?

Foundayo is orforglipron, a GLP-1 receptor agonist: it switches on the receptor for GLP-1, a gut hormone that helps set appetite and how much is eaten1. It lowers food intake, most likely through appetite, and slows the stomach, most of all after the first dose1. In animal studies it reached the brain areas that regulate appetite and food intake1; that part is from animals, not people.

Three circles with areas to scale by molecular weight: semaglutide about 4,100, tirzepatide about 4,800, and orforglipron about 900, a fifth of semaglutide
Look at the size: orforglipron is about a fifth of a GLP-1 peptide, which is why it absorbs like an ordinary pill.

It is not a peptide. Semaglutide (Wegovy) and tirzepatide (Zepbound) are peptides: chains of amino acids, about 4,100 and 4,800 daltons in size75. The stomach digests peptides the way it digests protein, so the Wegovy pill needs an empty stomach, no more than 4 ounces of plain water and a 30-minute wait before food, drinks or other pills7. Orforglipron is a small molecule built by chemistry, about 900 g/mol as the calcium salt in the tablet, a fifth of semaglutide's size1. It goes in like an ordinary pill: 77% of a 0.8 mg dose reached the blood1.

So the label's routine is short: one tablet a day, swallowed whole, never more than one, with or without food1. With food, total exposure came out 19% lower in the label's study, which the label calls not clinically relevant1. Its half-life, the time the body takes to clear half of it, is about 29 to 49 hours1, against about 5 days for tirzepatide5. Hence a daily pill, as the chart shows.

Try it

How Orforglipron builds up

An estimate from a half-life of about 39 hours, one dose a day for four weeks. The shape of the level, not a measurement.

Try your own scheduleOrforglipron in the library

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault reminds you at the time you set each day and logs each tablet with one tap, so a run of missed days shows long before it reaches seven.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What is Foundayo approved for?

Weight. FDA approved Foundayo as a new molecular entity on April 1, 20262. As of November 2026 (label version 10, published on DailyMed on August 13, 2026), its one approved use is to reduce excess body weight and keep it off long term, together with a reduced-calorie diet and more physical activity, in adults with obesity, or with overweight and at least one weight-related condition1. The label advises against taking it with another GLP-1 medicine1.

It is not approved for type 2 diabetes, though the ACHIEVE trials tested it there. Zepbound, by comparison, is also approved for obstructive sleep apnoea in adults with obesity5, and the Wegovy shot's label adds lowering the risk of major heart events in adults with heart disease and a liver use (MASH)7. Which of these suits one person, and at what dose, is the prescriber's decision.

How much weight did people lose on Foundayo compared with the shots?

Less than on Zepbound or the Wegovy shot, with one tie: in type 2 diabetes it matched the Wegovy shot's long-standing 2.4 mg dose. Every number comes from each drug's FDA label, at its top dose (for Wegovy also 2.4 mg): the average weight change, with placebo (a dummy pill or shot) in brackets, and the share who lost at least 15% of their starting weight.

Medicine (trial)How it's takenWeeksWeight change (placebo)Lost 15% or more (placebo)
No diabetes
Foundayo 17.2 mg (ATTAIN-1)1Pill, daily72−11.1% (−2.1%)35.9% (6.0%)
Zepbound 15 mg (SURMOUNT-1)5Shot, weekly72−20.9% (−3.1%)70.6% (8.8%)
Wegovy 2.4 mg (STEP 1)7Shot, weekly68−14.9% (−2.4%)47.9% (4.8%)
Wegovy 7.2 mg (STEP UP)7Shot, weekly72−18.8% (−3.9%)63.8% (7.5%)
Wegovy pill 25 mg (OASIS 4)7Pill, daily64−13.6% (−2.4%)47% (5.5%)
Type 2 diabetes
Foundayo 17.2 mg (ATTAIN-2)1Pill, daily72−9.6% (−2.5%)25.9% (3.1%)
Zepbound 15 mg (SURMOUNT-2)5Shot, weekly72−14.7% (−3.2%)48.0% (2.7%)
Wegovy 2.4 mg (STEP 2)7Shot, weekly68−9.6% (−3.4%)25.1% (4.3%)
Wegovy 7.2 mg (STEP UP T2D)7Shot, weekly72−13.2% (−3.8%)39.8% (6.9%)
Average weight change on each drug beside its placebo, by trial: without diabetes Foundayo −11.1% (placebo −2.1%), Zepbound −20.9%, Wegovy 2.4 mg −14.9%, Wegovy 7.2 mg −18.8%, the Wegovy pill −13.6%; with type 2 diabetes Foundayo −9.6% (−2.5%), Zepbound −14.7%, Wegovy 2.4 mg −9.6%, Wegovy 7.2 mg −13.2%
Look at the gap between each pair of dots: that is the drug's effect beyond placebo, and in type 2 diabetes Foundayo's gap sits beside the Wegovy shot's at 2.4 mg, and below it at 7.2 mg.

Taking placebo away, Foundayo's top dose came out 9.0 points ahead in ATTAIN-1 and 7.1 in ATTAIN-21; Zepbound's 15 mg 17.8 and 11.65; the Wegovy shot 12.4 and 6.2 at 2.4 mg, 14.9 and 9.4 at 7.2 mg7.

The trials used an earlier formulation at 6, 12 and 36 mg; the label reports those groups as equivalent tablet doses, 5.5, 9 and 17.2 mg1, and ACHIEVE-4 states that 36 mg equals the 17.2 mg tablet12. ATTAIN-1's paper prints its 36 mg result as −11.2%3, a decimal from the label's re-analysis; ATTAIN-2's paper and label agree at −9.6%4.

Is it fair to compare these trials?

Only roughly: no trial has tested Foundayo against Zepbound or the Wegovy shot. Each row is a separate trial, with its own volunteers, length (64 to 72 weeks) and way of filling in the weights of people who dropped out157.

The rows do share one thing. An estimand is the precise question a trial's main result answers. Every row is its label's intention-to-treat result: the average change in everyone randomised, whether or not they kept taking the drug, which the trials call the treatment-regimen or treatment-policy estimand135678. Analyses that count only people who stayed on the drug usually come out higher, so never set one kind beside the other. The labels also say side-effect rates from different drugs' trials cannot be compared directly1.

Starting weights were close, about 100 to 113 kg (220 to 250 lb) across these trials157, so a percentage means similar pounds in each.

How did orforglipron do in type 2 diabetes (ACHIEVE)?

Well on blood sugar, and it beat the semaglutide pill head to head. HbA1c is a blood test that reflects average blood sugar over about three months; the change is in percentage points. These trials use the trial doses (36 mg is the 17.2 mg tablet12).

TrialAgainstWeeksStart HbA1cOrforglipronComparator
ACHIEVE-19Placebo, diet and exercise only408.0%−1.24 (3 mg), −1.47 (12 mg), −1.48 (36 mg)−0.41
ACHIEVE-210Dapagliflozin 10 mg, on metformin408.14%−1.23 (3 mg), −1.50 (12 mg), −1.56 (36 mg)−0.81
ACHIEVE-311Oral semaglutide, the drug in Rybelsus, on metformin528.3%−1.71 (12 mg), −1.91 (36 mg)−1.23 (7 mg), −1.47 (14 mg)

ACHIEVE-3 is this guide's only trial against another GLP-1: 1,698 adults, both drugs as daily pills. Both orforglipron doses lowered HbA1c more than both semaglutide doses; 36 mg against 14 mg differed by 0.44 points11. The price was tolerability: stomach side effects in 59% and 58% on orforglipron against 37% and 45% on semaglutide, 9% and 10% stopping for side effects against 4% and 5%, and a larger rise in pulse, 3.7 and 4.7 beats a minute against 1.0 and 1.511.

ACHIEVE-4 checked the heart. In 2,749 adults with type 2 diabetes and heart or kidney disease, followed for a median of 2 years, major heart events came in 4.2% on orforglipron and 5.0% on insulin glargine, which met the trial's test for being no worse12. The Wegovy pill's own routine has its own guide.

Can Foundayo keep weight off after a shot?

In one trial, mostly. ATTAIN-MAINTAIN moved people who had lost weight on tirzepatide or semaglutide shots to daily orforglipron or a placebo pill for 52 weeks13. Among those whose weight had plateaued, people coming off tirzepatide kept 74.7% of their loss on orforglipron against 49.2% on placebo; people coming off semaglutide kept 79.3% against 37.6%13.

The trial had no group that simply stayed on the shot, and it lasted one year, so it shows the pill beats stopping, not that it matches continuing13. The Foundayo label sets no schedule for moving over from a shot1.

How does the label step up the dose?

Slowly, a month at a time, to keep stomach side effects down1. These are the label's steps, not a plan for one person:

  • 0.8 mg once a day for at least 30 days, then 2.5 mg for at least 30 days, then 5.5 mg1.
  • From 5.5 mg, the dose may rise to 9 mg, 14.5 mg and 17.2 mg, at least 30 days apart, by response and tolerability; 17.2 mg is the maximum1.
  • With a strong CYP3A4 inhibitor (a group of medicines that slows how the liver clears orforglipron), the label caps the dose at 9 mg a day1.
  • A missed tablet is taken as soon as possible, never doubled; after 7 or more missed days in a row, the climb restarts at a lower dose1.
  • Oral birth-control pills may work less well: the label advises a non-oral method, or adding a barrier method, for 30 days after starting and after each step-up1.
A staircase of six daily doses, each held at least 30 days: 0.8, 2.5 and 5.5 mg drawn solid as the schedule, then 9, 14.5 and 17.2 mg dashed, taken by response and tolerability
Look at where the steps turn dashed: past 5.5 mg each rise is a choice, not a schedule.

At the fastest pace that puts 17.2 mg about five months in, near the 20 weeks Zepbound's climb to 15 mg took in SURMOUNT-16.

PepVault reminds you at the time you set each day and logs each tablet with one tap, so a run of missed days shows long before it reaches seven. Set reminders in PepVault

Its weight and side-effect logs keep each month's step beside how you felt, ready for the prescriber's next decision. Track your weight in PepVault

What side effects come with Foundayo?

Mostly stomach effects, highest during the step-ups and easing over time1. In the label's pool of both weight trials, on 17.2 mg against placebo: nausea 35% against 10%, diarrhoea 25% against 11%, constipation 24% against 9% and vomiting 24% against 4%1. Most stomach effects were mild or moderate, and 10% on 17.2 mg stopped because of side effects, against 3% on placebo1. Smaller, slower meals are the usual advice, and the label asks for steady fluids when stomach effects hit1. The full list is on our orforglipron side-effects page.

Like the shots, it carries a boxed warning on thyroid C-cell tumours, worded differently: the rodent tumours behind the shots' warning come from the GLP-1 receptor acting in rats and mice, and orforglipron does not act in those animals; it caused no tumours there, and whether the finding matters for people has not been determined1. It is not for anyone with a personal or family history of medullary thyroid cancer or MEN 21.

Commonly reported: liking that the tablet goes down with breakfast or coffee, unlike the Wegovy pill's morning wait; queasiness or fullness for a few days after each monthly step; and appetite quieting within the first weeks.

When to get help Severe stomach pain that does not settle, with or without vomiting, can be pancreatitis, which the label lists, so that is the moment to get medical help the same day1.

Track it in the app

Sources

  1. FOUNDAYO (orforglipron) tablets prescribing information, DailyMed, SPL version 10, August 13, 2026 dailymed.nlm.nih.gov
  2. Drugs@FDA: NDA 220934, FOUNDAYO tablets, original approval April 1, 2026 accessdata.fda.gov
  3. Wharton S et al.; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025. PubMed 40960239
  4. Horn DB et al. Orforglipron for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3 trial. Lancet. 2026. PubMed 41275875
  5. ZEPBOUND (tirzepatide) prescribing information, DailyMed, SPL version 40, September 2, 2026 dailymed.nlm.nih.gov
  6. Jastreboff AM et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PubMed 35658024
  7. WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed, SPL version 19, June 30, 2026 dailymed.nlm.nih.gov
  8. Wilding JPH et al.; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. PubMed 33567185
  9. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes (ACHIEVE-1). N Engl J Med. 2025. PubMed 40544435
  10. Orforglipron compared with dapagliflozin in adults with type 2 diabetes on metformin (ACHIEVE-2): a phase 3 trial. Lancet. 2026. PubMed 42259339
  11. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3). Lancet. 2026. PubMed 41765029
  12. Klein et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes (ACHIEVE-4). Lancet. 2026. PubMed 42815506
  13. Aronne LJ et al. Orforglipron for maintenance of body weight reduction: the phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. PubMed 42120723

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo